AHAgnes Marije Hoogland

Agnes Marije Hoogland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agnes Marije Hoogland has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer

    by A. Marije Hoogland, René Böttcher, Esther Verhoef, Guido Jenster, Geert J.L.H. van Leenders

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> A. Marije Hoogland1, René Böttcher2, 3, Esther Verhoef1, Guido Jenster2, Geert J.L.H. van Leenders1 1Departments of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands 2Departments of Urology, Erasmus Medical Center, Rotterdam, The Netherlands 3Department of Bioinformatics, University of Applied Sciences Wildau, Wildau, Germany Correspondence to: A. Marije Hoogland, email: A.M.Hoogland@erasmusmc.nl Keywords: prostate cancer, RNA sequencing, laser capture microdissection, immunohistochemistry Received: December 30, 2015 Accepted: April 25, 2016 Published: May 13, 2016


  • Open Access

    Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy

    by Chinyere Ibeawuchi, Hartmut Schmidt, Reinhard Voss, Ulf Titze, Mahmoud Abbas, Joerg Neumann, Elke Eltze, Agnes Marije Hoogland, Guido Jenster, Burkhard Brandt, et al.

    The multifocal nature of prostate cancer (PCa) creates a challenge to patients’ outcome prediction and their clinical management. An approach that scrutinizes every cancer focus is needed in order to generate a comprehensive evaluation of the disease, and by correlating to patients’ clinico-pathological information, specific prognostic biomarker can be identified. Our study utilized the Affymetrix SNP 6.0 Genome-wide assay to investigate forty-three fresh frozen PCa tissue foci from twenty-three patients. With a long clinical follow-up period that ranged from 2.0–9.7 (mean 5.4) years, copy number variation (CNV) data was evaluated for association with patients’ PSA status during follow-up. From our results, the loss of unique genes on 10q23.31 and 10q23.2–10q23.31 were identified to be significantly associated to PSA recurrence (p < 0.05). The implication of PTEN and FAS loss (10q23.31) support previous reports due to their critical roles in prostate carcinogenesis. Furthermore, we hypothesize that the PAPSS2 gene (10q23.2–10q23.31) may be functionally relevant in post-operative PSA recurrence because of its reported role in androgen biosynthesis. It is suggestive that the loss of the susceptible region on chromosome 10q, which implicates PTEN, FAS and PAPSS2 may serve as genetic predictors of PSA recurrence after radical prostatectomy.


  • Open Access

    Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review

    by A. Marije Hoogland, Charlotte F. Kweldam, Geert J. L. H. van Leenders

    Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival. Therefore, individual assessment of a tumor’s aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens. However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies.


  • Validation of stem cell markers in clinical prostate cancer: α6-Integrin is predictive for non-aggressive disease

    by A. Marije Hoogland, Esther I. Verhoef, Monique J. Roobol, Fritz H. Schröder, Mark F. Wildhagen, Theo H. van der Kwast, Guido Jenster, Geert J.L.H. van Leenders

    BACKGROUND Stem cells are postulated to mediate prostate cancer progression, and represent a small fraction of the entire tumor. Various proteins (α2‐integrin, α6‐integrin, CD117, CD133, EZH2, OCT3/4) are associated with a prostate cancer stem cell phenotype in cell lines and xenografts. Our objective was to investigate expression of stem cell markers in clinical prostate cancer in relation to outcome. METHODS We validated immunohistochemical expression of stem cell markers in 481 prostate cancer patients and correlated expression with clinicopathologic parameters. RESULTS Sporadic expression of α2‐integrin was present in a fraction of tumor cells ( 10 ng/ml (P = 0.04). α6‐Integrin expression (P = 0.01), Gleason score P < 0.01) and pT2‐disease (P = 0.02). α6‐integrin was predictive for biochemical recurrence (P < 0.01), local recurrence (P = 0.03) and disease specific death (P = 0.03). EZH2 expression was generally low with 2.6% of tumors showing ≥1% positive cells. EZH2 was associated with Gleason score ≥7 (P = 0.01) and biochemical recurrence (P = 0.01). We did not identify expression of CD117, CD133, and OCT3/4 in prostate cancer samples. CONCLUSIONS Expression of α2‐integrin and EZH2 in a small fraction of prostate cancer cells is supportive for their role as stem cell marker. Although α6‐integrin was not a unique stem cell marker, it was predictive for prostate cancer biochemical and local recurrence, and disease specific death. The validity of CD117, CD133, and OCT3/4 as prostate cancer stem cell marker is questionable since these proteins were not expressed in clinical prostate cancer. Prostate 74:488–496, 2014.


  • Open Access

    Genome-Wide Investigation of Multifocal and Unifocal Prostate Cancer — Are They Genetically Different?

    by Chinyere Ibeawuchi, Hartmut Schmidt, Reinhard Voss, Ulf Titze, Mahmoud Abbas, Joerg Neumann, Elke Eltze, Agnes Marije Hoogland, Guido Jenster, Burkhard Brandt, et al.

    Prostate cancer is widely observed to be biologically heterogeneous. Its heterogeneity is manifested histologically as multifocal prostate cancer, which is observed more frequently than unifocal prostate cancer. The clinical and prognostic significance of either focal cancer type is not fully established. To investigate prostate cancer heterogeneity, the genetic profiles of multifocal and unifocal prostate cancers were compared. Here, we report observations deduced from tumor-tumor comparison of copy number alteration data of both focal categories. Forty-one fresh frozen prostate cancer foci from 14 multifocal prostate cancers and eight unifocal prostate cancers were subjected to copy number variation analysis with the Affymetrix SNP 6.0 microarray tool. With the investigated cases, tumors obtained from a single prostate exhibited different genetic profiles of variable degrees. Further comparison identified no distinct genetic pattern or signatures specific to multifocal or unifocal prostate cancer. Our findings suggest that samples obtained from multiple sites of a single unifocal prostate cancer show as much genetic heterogeneity and variability as separate tumors obtained from a single multifocal prostate cancer.


  • ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

    by A Marije Hoogland, Guido Jenster, Wytske M van Weerden, Jan Trapman, Theo van der Kwast, Monique J Roobol, Fritz H Schröder, Mark F Wildhagen, Geert Jlh van Leenders


  • Cysteine‐rich secretory protein 3 and β‐microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome

    by Agnes Marije Hoogland, Anna Dahlman, Kees J. Vissers, Tineke Wolters, Fritz H. Schröder, Monique J. Roobol, Anders S. Bjartell, Geert J.L.H. van Leenders

    What’s known on the subject? and What does the study add? Cysteine‐rich secretory protein 3 (CRISP‐3) and β‐microseminoprotein (β‐MSP) both have independent prognostic value for biochemical recurrence of prostate cancer after radical prostatectomy. The study investigates whether CRISP‐3 and β‐MSP have prognostic value on diagnostic prostate needle‐biopsies, which are more relevant for therapeutic decision‐making. On needle‐biopsies CRISP‐3 and β‐MSP do not have significant prognostic value. OBJECTIVES: • To investigate whether cysteine‐rich secretory protein 3 (CRISP‐3) and/or β‐microseminoprotein (β‐MSP) expression in diagnostic prostate needle biopsies have predictive value for prostate cancer (PC) on radical prostatecomy (RP). • To evaluate their potential clinical implementation in a preoperative setting. PATIENTS AND METHODS: • In total, 174 participants from the European Randomized Study of Screening for Prostate Cancer, Rotterdam section, treated by RP for PC were included in the present study. • CRISP‐3 and β‐MSP immunohistochemistry was performed on corresponding diagnostic needle biopsies. • Outcome was correlated with clinicopathological parameters (prostate‐specific‐antigen, PSA; number of positive biopsies; Gleason score, GS; pT‐stage; surgical margins at RP) and significant PC at RP (pT3/4, or GS > 6, or tumour volume ≥0.5 mL) in the total cohort ( n = 174) and in a subgroup with low‐risk features at biopsy (PSA ≤ 10 ng/ml, cT ≤ 2, PSA density n = 87). RESULTS: • β‐MSP and CRISP‐3 expression in PC tissue was heterogeneous, with variable staining intensities occurring in the same tissue specimen. • High expression of β‐MSP significantly correlated with GS < 7 at RP; it was not a predictor for significant PC at RP neither in the total group ( n = 174; odds ratio, OR, 0.319; 95% confidence interval, CI, 0.060–1.695; P = 0.180), nor in the low‐risk group ( n = 87; OR, 0.227; 95% CI, 0.040–1.274; P = 0.092). • CRISP‐3 expression was not related to clinicopathological parameters, and did not predict significant PC at RP in the total group ( n = 174; OR, 1.056; 95% CI, 0.438–2.545; P = 0.904) or the low‐risk group ( n = 87; OR, 1.856; 95% CI, 0.626–5.506; P = 0.265). CONCLUSIONS: • High β‐MSP expression correlated with low GS in subsequent RP specimens, supporting the view that β‐MSP exerts a tumour‐suppressive effect. • No significant prognostic value of β‐MSP or CRISP‐3 in prostate needle biopsies for significant PC at RP was found. • β‐MSP or CRISP‐3 do not have additional value in the therapeutic stratification of patients with PC.